Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$60.42
-1.0%
$51.12
$22.28
$67.74
$24.20B1.057.10 million shs11.69 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$277.12
+0.4%
$293.24
$239.25
$385.22
$30.30B0.49283,982 shs218,594 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.01
+5.6%
$29.47
$10.70
$34.51
$23.17B1.135.21 million shs10.30 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$86.24
-11.1%
$75.55
$14.00
$102.06
$8.43B3.051.29 million shs4.04 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-0.95%-2.23%+28.88%+12.79%+125.45%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+0.36%+5.50%-10.68%+0.06%+3.87%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+5.59%+9.01%+13.52%+24.35%+194.71%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-11.14%-1.43%+16.46%+81.48%+459.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$60.42
-1.0%
$51.12
$22.28
$67.74
$24.20B1.057.10 million shs11.69 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$277.12
+0.4%
$293.24
$239.25
$385.22
$30.30B0.49283,982 shs218,594 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$34.01
+5.6%
$29.47
$10.70
$34.51
$23.17B1.135.21 million shs10.30 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$86.24
-11.1%
$75.55
$14.00
$102.06
$8.43B3.051.29 million shs4.04 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-0.95%-2.23%+28.88%+12.79%+125.45%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+0.36%+5.50%-10.68%+0.06%+3.87%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+5.59%+9.01%+13.52%+24.35%+194.71%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-11.14%-1.43%+16.46%+81.48%+459.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$36.60-39.42% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.93
Moderate Buy$390.0040.73% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-1.23% Downside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.00
Buy$95.8311.12% Upside

Current Analyst Ratings Breakdown

Latest SYRE, ONC, MRNA, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$115.00 ➝ $135.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/16/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Reiterated RatingOutperform$100.00
6/15/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$98.00 ➝ $112.00
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
6/4/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Reiterated RatingSell (D-)
6/4/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$102.00 ➝ $115.00
6/4/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeHoldStrong-Buy
6/2/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$425.00 ➝ $436.00
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B12.33N/AN/A$22.14 per share2.73
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B5.69$3.92 per share70.65$39.77 per share6.97
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M2,961.55N/AN/A$7.35 per share4.63
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K8,414.70N/AN/A$7.21 per share11.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4762.0026.24N/A8.94%12.06%6.69%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)

Latest SYRE, ONC, MRNA, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2026Q4 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million
5/5/2026Q1 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
8.97
8.97

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7386.84 million73.22 millionOptionable

Recent News About These Companies

Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)
Spyre Therapeutics Inc SYRE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna stock logo

Moderna NASDAQ:MRNA

$60.42 -0.58 (-0.95%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$60.45 +0.03 (+0.04%)
As of 06/24/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$277.12 +0.99 (+0.36%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$273.85 -3.27 (-1.18%)
As of 06/24/2026 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$34.01 +1.80 (+5.59%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$34.38 +0.37 (+1.07%)
As of 06/24/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$86.24 -10.81 (-11.14%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$84.36 -1.88 (-2.18%)
As of 06/24/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.